KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTER

KFSHRC has conducted pharmacogenetic analysis for over 1,500 patients, tailoring medications to individual DNA, reducing adverse drug reactions, and improving treatment efficiency. The service initially focused on cardiology and neurology, expanding to organ transplant patients, with plans to extend to all specialties. KFSHRC won the 2024 Gartner Eye on Innovation Award for its Pharmacogenomics Program and ranks highly in global healthcare rankings.

KFSHRC concluded its participation at the 2024 NYC C3 Summit Davos, highlighting its role in healthcare innovation. Dr. Björn Zoéga received the 2024 C3 Global Innovative Healthcare & Impact Transformation Award. Sessions focused on biotechnology, AI, robotics, and precision medicine.

KFSHRC integrates genomic profiling and pharmacogenomics into clinical practice, offering targeted treatments for complex diseases. Dr. Salah Baz highlights personalized healthcare advancements at the C3 Summit. KFSHRC's precision cancer therapies and Whole Genome Sequencing significantly improve patient care and reduce costs. The Clinical Pharmacogenomics Service tailors drug treatments, enhancing safety and effectiveness.

KFSHRC leads Saudi Arabia's biotech advancements in genomics, CAR T-cell therapy, and sustainable healthcare, aiming to become a global powerhouse.